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Abstract
Background: Data on sequential therapy in patients with metastatic renal cell carcinoma (mRCC) and intrinsic
resistance to receptor tyrosine kinase inhibitor (rTKI) treatment remains vague.
Methods: We retrospectively studied treatment characteristics and outcome of mRCC patients refractory to first
rTKI therapy.
Results: Thirty-five mRCC patients (male, 18; female, 11) with primary resistance to first rTKI therapy (sunitinib, n
= 28; sorafenib, n = 7) and a median treatment interval of 2.4 months (1 - 4.6) were identified. In 22 patients,
progressive disease (PD) was determined by a new metastatic lesion. Of these, 16 patients received subsequent
therapy with 12 patients remaining refractory and 4 patients achieving disease stabilization. In 13 patients
continuous growth of existing metastatic lesions determined PD. Of these, 9 received sequential therapy with 6
achieving disease stabilization. Altogether, 25 patients were treated sequentially (rTKI: n = 15; mTOR-inhibitor: n
= 10) and achieved a median PFS of 3.2 months (range, 1-16.6). Fifteen patients failed to respond to either line
of therapy. Disease control was not associated with type of subsequent therapy. Median OS was 14.9 months
(CI: 5.5-24.4).
Conclusion: Intrinsic resistance to rTKI is associated with a low chance of response to sequential therapy and a
poor prognosis in mRCC patients.
Background
During the last years potent therapeutic options evolved
for patients with mRCC [1-4]. The introduction of tar-
geted agents has significantly improved the treatment per-
spectives and prognosis of these patients. The majority of
patients with good and intermediate prognosis according
to the MSKCC criteria are treated with rTKI, particularly
sunitinib, based on the results of two meta-analyses [5,6].
In spite of this progress in treatment options, a relevant
subset of patients remains refractory to first rTKI therapy.
On a molecular level, rTKIs target the vascular endothelial
growth factor (VEGF) pathway to induce hypoxia, thereby
inhibiting tumor growth. However, recent reports suggest
that hypoxia may also select for a more malignant RCC
phenotype, which may aggregate metastatic development
and prone cells to insensitivity for antiangiogenic treat-
ment [7]. Another possible explanation for the resistance
to rTKI treatment could be attributed the fact that tumor
cells can overcome the noxious rTKI hypoxic microenvir-
onment by switching to invasive epithelial-mesenchymal
transition [8].
The phenomenon of intrinsic resistance to rTKI is not
well understood, and it remains unclear whether
patients primary refractory to rTKI might benefit from
other treatment regimens during sequential therapy. In
the present study we aimed to characterize patients with
intrinsic resistance to rTKI treatment and analyse their
susceptibility to sequential therapy.
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Methods
We retrospectively reviewed the records of 189 patients
treated with first line rTKI therapy (sunitinib or sorafe-
nib) for mRCC at two large German academic centers.
Medical records were retrieved and analyzed retrospec-
tively in accordance with the regulatory agreement of
the local ethics committee and the Declaration of Hel-
sinki, approved by the local ethics committee. Thirty-
five patients (18.5%) who had progressive disease (PD)
as best response were considered intrinsic resistant and
eligible for further analyses. Patient characteristics are
shown in detail in table 1. All patients clearly experi-
enced a progressive disease without any sign of mixed
response regardless whether a new metastatic lesion
developed or not. Second line targeted therapy (SL) con-
sisted of another TKI (sunitinib or sorafenib) or an
mTOR inhibitor (everolimus, temsirolimus). Third and
fourth line therapy was individualized and included
dovitinib, alpha-interferon, or bevacizumab plus alpha-
interferon. Any therapy prior to first rTKI treatment
was not counted as first line therapy but as previous
therapy. Eight (22.9%) patients were treated on first
rTKI therapy within prospective trials, and 17 (48.6%)
patients were at least once treated within a prospective
trial.
Sunitinib was administered daily either as 50 mg or
37.5 mg orally over 4 weeks followed by a two week wash-
out period. Sorafenib was administered continuously at a
full dose of 400 mg orally twice a day. Dosing for everoli-
mus was 10 mg daily and for temsirolimus 25 mg intrave-
nously once weekly. All agents were administered until
disease progression, death, or intolerable toxicity. Objective
response was determined every second cycle of sunitinib or
every two to three months for all other agents according to
the standard Response Evaluation Criteria in Solid Tumors
(RECIST) [9]. PFS and OS were calculated from initiation
of first rTKI therapy using the Kaplan-Meier-method.
Furthermore, potential relationships between patients’
characteristics (age, gender, MSKCC risk and ECOG
performance group) with best response on SL and num-
ber of affected organ sites, new metastatic site at PD,
localisation of PD and time to progression on prior
treatment were assessed in an exploratory manner [10].
Statistics
Associations between main characteristics and response
to treatment were explored using the chi-square test/
Fisher’s exact test. A p-value < 0.05 was considered sta-
tistically significant. PFS and OS were estimated using
the Kaplan-Meier method with the log-rank test.
Results
Thirty-five mRCC patients (18 male and 11 female) pri-
mary resistant to rTKI therapy with a median age of 62
years (range 39 - 79 years) were identified. All patients
had radical nephrectomy prior to systemic therapy.
Fourteen patients received immunotherapy before treat-
ment with targeted agents over a median period of 3.6
months (range 0.5-10.3). Best response upon immu-
notherapy was stable disease in six patients. Initial rTKI
therapy included sunitinib (n = 28) and sorafenib (n =
7). The median overall duration of first rTKI treatment
was 2.4 (1-4.6; 95%CI: 2.2-2.6) months, specifically 2.5
(1-4.6; 95% CI: 2.3-2.7) months for sunitinib and 1.7 (1-
3.2; 95% CI: 1.1-2.3) months for sorafenib (p = 0.130).
The median PFS of the 25 patients who underwent
sequential treatment with a targeted agent was 3.2
months (1 -16.6; 95% CI: 1.7-4.6). The remaining 10
patients did not receive any additional targeted therapy.
Eight of them died of the disease after a median OS of
3.0 (95% CI: 1-5.1) months and 2 patients remained on
best supportive care (BSC). Table 2 depicts the objective
response assessment according to the line of targeted
therapy. MSKCC prognosis group, the location or the
number of metastases as well as the type of targeted
agent were not associated with response to sequential
therapy on fisher’s exact test (data not shown). In 22
patients, PD during first rTKI therapy was determined
by the occurrence of a new metastatic lesion. Of these,
16 patients received sequential treatment. 12 patients
remained refractory to subsequent therapy while four
patients had disease stabilization (mTOR: n = 2; rTKI:
n = 2). 13 patients had PD by continuous growth of the
initial metastatic lesions. Of these, 9 patients received
sequential treatment, and 6 patients achieved disease
stabilization (mTOR: n = 3; rTKI: n = 3) (Figure 1).
Table 1 Patients’ characteristics
n (%)
Sex male 26 (74.3)
female 9 (25.7)
total 35 (100)




ECOG status 0 21 (60)
1 9 (25.7)
> 1 1 (2.9)
unknown 4 (11.4)
Histology clear cell 29 (82.7)
papillary 4 (11.4)
other 2 (5.9)
Previous immunotherapy 14 (40)
Abbreviations:
MSKCC - Memorial Sloan-Kettering Cancer Center;
ECOG - Eastern Cooperative Oncology Group;
rTKI - receptor tyrosine kinase inhibitor.
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Disease control (PR or SD) by any of the sequential
therapy lines was achieved in 15 patients (42.8%). Only
14 and 7 patients received a third and fourth line of tar-
geted treatment with a median estimated PFS of 1.9 (1-
15; 95% CI: 1-3) and 2.6 (1-9; 95% CI: 2.1-3.1) months,
respectively. Overall, only one patient accomplished a
partial response on sequential treatment with temsiroli-
mus. The median OS from the first rTKI therapy was
14.9 (95% CI: 5.5-24.4) months. Patients with new meta-
static lesions on first rTKI therapy had a shorter, how-
ever statistically not significant, median OS of 10.7 (95%
CI: 10.9-27.2) months than patients with growth of the
initial lesions achieving a median OS of 19.1 (95% CI:
1.8-19.6) months (p = 0.161).
Discussion
In this study we report on 35 patients with intrinsic
resistant mRCC to rTKI treatment. This subset of
patients seems to be characterized by a low likelihood
of response to any form of available targeted therapy,
with mTOR inhibitors being equally inefficacious as
switching to another TKI. The median OS from initia-
tion of first rTKI therapy was only 14.9 months and
the median PFS upon second line targeted therapy was
limited to 3.5 months with a disease control rate of
roughly 40% in the sequence setting. The primary
development of a new metastatic lesion during first
rTKI treatment may indicate a particularly unfavour-
able prognosis.
Table 2 Response assessment according to line and type of targeted therapy
Line of targeted therapy PFS in months (range) All Sun Sor Eve Tem Other
1st 2.4 PR
(1-4.6) SD
PD 35 28 7
2nd 3.2 PR
(1-16.6) SD 10 1 4 3 2
PD 15 2 8 4 1
3rd 1.9 PR 1 1
(1-15) SD 4 1 1 2
PD 9 6 1 2
4th 2.6 PR
(1-9) SD 4 1 3
PD 3 1 1 1
Abbreviations:PFS - progression free survival; Sun - sunitinib; Sor - sorafenib; Eve - everolimus; Tem - temsirolimus; PR - partial response; SD - stable disease; PD -
progressive disease
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Figure 1 Disease course of mRCC patients refractory to first rTKI treatment. PD - progressive disease; SD - stable disease; ST - sequential
therapy; BSC - best supportive care; rTKI - receptor tyrosine kinase inhibitor.
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In spite of recent substantial advances in treatment
options the salvage strategy for patients with intrinsic
resistance to rTKI treatment is not well defined.
According to our data this subgroup of patients may
have a low chance of overcoming rTKI resistance or
responding to the available sequential treatment options.
The rationale for sequential therapy with mTOR inhibi-
tors in rTKI refractory patients lies in the expectation
that resistance of the tumor to rTKI treatment may be
reversed by targeting a different signaling pathway
[11,12]. In the placebo-controlled phase 3 RECORD-1
trial everolimus turned out to be an efficacious treat-
ment option following failure of rTKI therapy [2]. How-
ever, disease control can be achieved by rTKI treatment
in the majority of treatment-naïve mRCC patients, sug-
gesting underlying sensitivity to VEGFR-targeted agents.
Whether mTOR inhibitors exert superior clinical activity
in intrinsic resistant disease remains unknown.
Nonetheless, prospective data on the best sequential
therapy among the available sequence options in mRCC
are still lacking. In their retrospective study Vickers et al.
reported that patients receiving another VEGF targeted
therapy in the sequence setting may experience a longer
progression free survival compared to those treated with
mTOR inhibitors [13]. However, among the 216 analyzed
patients with a second line therapy only 24 were treated
with mTOR inhibitors and as few as three of them
received everolimus, so that no valid comparison can be
made between everolimus or other options in this setting.
In another study Garcia et al. observed a PFS of 4.4
months in 49 patients treated with sorafenib following
progression on either sunitinib or bevacizumab [14].
However, the vast majority of these patients had some
benefit from first line therapy and developed resistance
after several treatment cycles. Compared to these studies
our data is based exclusively on patients with intrinsic
rTKI resistance. In this subset of patients we observed no
convincing efficacy of either of the common sequence
therapy regimens. The small number of patients and the
retrospective nature of our analysis limit the validity of
our observations. The data from prospective randomized
trials will certainly clarify some of these issues. However,
our data indicate that there is a substantial subset of
patients who will not respond to either targeted therapy
option available today.
In general, sensitivity to targeted agents occurs when the
tumor depends on the constitutive activity of signaling
pathways for growth and progression. On the other hand
resistance may develop when genetic alterations make the
targeted proteins inaccessible to drug binding, activate
alternative signaling pathways or upregulate molecule
expression to compensate for the inhibition. Indeed, two
general modes of resistance to angiogenesis inhibitors tar-
geting the VEGF pathway have been proposed: adaptive
(evasive) resistance, which occurs after a period of tumor
control, and intrinsic (pre-existing) non-responsiveness
without any therapeutic benefit [15]. Alternative pro-
angiogenic signaling pathways within the tumor, recruit-
ment of bone marrow-derived pro-angiogenic cells,
increased protection of tumor vasculature by pericytes,
and increased tumor cell invasiveness to escape oxygen
and nutrient deprivation may all constitute escape
mechanisms in response to therapy or in response to the
selective pressures of the tumor microenvironment during
malignant progression [15]. Each targeted agent including
the various VEGF pathway inhibitors can cause a different
compensatory tumor response, explaining at least in some
parts the lack of cross-resistance and the potential benefit
of re-challenge strategies [16].
Despite the proposed common deficiency of VHL func-
tion in clear cell RCC, distinct clinical outcome has been
reported with current targeted therapies. These findings
suggest that underlying genetic abnormalities may be
more complex than previously assumed. A recent article
by Gordan addressed this crucial question and suggested
that HIF2 enhances c-MYC activity and promotes tumor
progression in VHL deficient tumors [17].
In tumors with acquired resistance, distinct mechanisms
of resistance have been detected [8,18,19]. Furthermore,
additional genetic abnormalities have been reported in
mRCC. The chromatin remodelling complex gene PBRM1
has been found to be mutated in 41% of 227 clearcell
RCC cases [20]. The functional role of PBMR1 in mRCC
remains to be determined, but these findings support the
notion of a genetic heterogeneity in clear cell mRCC,
which may determine intrinsic resistance in mRCC.
However, in intrinsic non-responsiveness the activation
of alternative pathways (e.g. TIE2/ANG-2) may be of key
relevance [3,21]. The currently used mTOR inhibitors, i. e.
rapalogs, selectively target mTOR complex (TORC)-1, but
leave TORC-2 unaffected. Developing inhibitors that tar-
get the kinase activity in both TORC1 and TORC2 could
result in increased antitumor effects and overcome some
of the obstacles associated with the TORC-1 inhibitors.
Moreover, mTOR/S6 K activation, insulin receptor sub-
strates 1 and 2 (IRS-1 and IRS-2) and insulin growth fac-
tor-1 (IGF-1) signaling, which all result in increased IGFR/
PI3K/Akt signaling, appear as attractive targets for further
drug development [22].
Current treatment strategies remain unsatisfactory in
patients with intrinsic resistance to VEGF targeted thera-
pies and underscore the medical need to advance the
treatment for these patients. Based on the preliminary
evidence of different genetic abnormalities in mRCC,
clinical trials with agents that interfere with HIF-signal-
ling or the chromatin remodelling complex seem suitable
for patients with intrinsic resistant mRCC. However,
gemcitabine-based chemotherapy has also been reported
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effective in single patients and may represent a distinct
approach to intrinsic resistance in RCC [23]. Certainly,
this subgroup of patients should be explored as a sepa-
rate entity in clinical trials. Remarkably, the overall
patients’ prognosis of our study in terms of PFS or OS
seems to be comparable to patients of the primary poor
prognosis group according to MSKCC criteria.
Conclusion
In conclusion, primary or intrinsic resistance to rTKI
therapy indicates a poor prognosis, particularly if new
metastatic sites develop. rTKI refractory mRCC patients
have a low chance to respond to sequential therapy irre-
spective of the type of treatment. Further characteriza-
tion of deregulated key signalling pathways in refractory
RCC appears of utmost importance for improving the
treatment perspectives. Other potential countermeasures
to overcome resistance include combination of VEGF or
mTOR inhibition with other signalling inhibitors or
with cytotoxic agents.
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